Sylvest Advisors LLC purchased a new stake in shares of Amdocs Limited (NASDAQ:DOX – Free Report) during the fourth quarter, Holdings Channel reports. The fund purchased 3,386 shares of the technology company’s stock, valued at approximately $288,000.
Several other institutional investors and hedge funds have also modified their holdings of DOX. Private Trust Co. NA raised its holdings in Amdocs by 62.9% during the third quarter. Private Trust Co. NA now owns 303 shares of the technology company’s stock valued at $27,000 after buying an additional 117 shares in the last quarter. Brooklyn Investment Group acquired a new position in shares of Amdocs during the 3rd quarter valued at about $28,000. Catalyst Capital Advisors LLC bought a new position in shares of Amdocs in the 3rd quarter valued at approximately $55,000. GAMMA Investing LLC lifted its holdings in Amdocs by 115.1% in the 3rd quarter. GAMMA Investing LLC now owns 800 shares of the technology company’s stock worth $70,000 after purchasing an additional 428 shares during the last quarter. Finally, Meeder Asset Management Inc. bought a new stake in Amdocs during the third quarter worth approximately $77,000. Institutional investors and hedge funds own 92.02% of the company’s stock.
Amdocs Price Performance
Shares of Amdocs stock opened at $88.19 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.20 and a quick ratio of 1.20. The company has a market cap of $9.96 billion, a PE ratio of 20.80, a price-to-earnings-growth ratio of 1.44 and a beta of 0.71. The firm has a fifty day moving average price of $85.97 and a two-hundred day moving average price of $86.33. Amdocs Limited has a fifty-two week low of $74.41 and a fifty-two week high of $94.04.
Amdocs Announces Dividend
Analyst Ratings Changes
A number of brokerages have recently weighed in on DOX. StockNews.com cut shares of Amdocs from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 14th. Barclays cut their target price on shares of Amdocs from $113.00 to $111.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Finally, Oppenheimer raised their price target on Amdocs from $98.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Amdocs has an average rating of “Moderate Buy” and an average price target of $101.20.
Check Out Our Latest Analysis on Amdocs
Amdocs Profile
Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.
Further Reading
- Five stocks we like better than Amdocs
- What Are Dividend Challengers?
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- 3 Dividend Kings To Consider
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- How to Short a Stock in 5 Easy StepsĀ
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Want to see what other hedge funds are holding DOX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amdocs Limited (NASDAQ:DOX – Free Report).
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.